PTCT / PTC Therapeutics stock jumps on royalty deal worth up to $1.5 billion

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q3 2023 Earnings Conference Call February 8, 2023 9:00 AM ET Company Participants Jane Hanlon - Associate Direct more_horizontal

PTC Therapeutics (NASDAQ: PTCT ) stock is falling on Friday after the biopharmaceutical company released its earnings report for the third quarter of more_horizontal

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2023, but it may be worthw more_horizontal

The biotech inked a lucrative royalty deal extension. Its counterparty is -- fittingly -- Royalty Pharma. more_horizontal

PTC Therapeutics shares PTCT, -0.53% jumped 12% premarket on Thursday after the company announced a deal with Royalty Pharma PLC RPRX, -3.58% to monet more_horizontal

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate more_horizontal

PTC Therapeutics (PTCT) will reduce its workforce in accordance with its strategic prioritization process. It will also submit a re-examination reques more_horizontal

Drugmaker PTC Therapeutics said on Thursday it plans to cut workforce, which would impact about 25% of the organization, as it aims to reduce its year more_horizontal